Reduced method robustness testing of analytical methods driven by a risk-based approach - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Reduced method robustness testing of analytical methods driven by a risk-based approach
A novel approach for assessing method robustness is described that uses risk-based assessment tools to identify, score, prioritise and then group method parameters. These parameters are then studied using reduced fractional factorial designs (termed Reduced Method Robustness) to evaluate the suitability of analytical methods prior to full validation. This simple approach helps to identify high risk method parameters earlier and can potentially save resource later in the development process.


Pharmaceutical Technology Europe
Volume 4, Issue 22

The single factors are high‑risk factors that cannot be easily combined with other factors. The excluded factors are those with low risk, or, in the case of split time, their effect will be accounted by another factor (split ratio).


Figure 5: Reduction of factors reduces resource required by 50%.
The 19 parameters detailed in Table 3 were risk assessed and a study containing only 7 instrumental factors were created; this was achieved by eliminating some parameters, combining other low risk parameters and combining parameters that were thought to have similar effects or affect different responses. The combination of parameters was quite aggressive to obtain a 7‑factor study where the number of experiments required was reduced. The resolution of the design was also kept to the minimum resolution (III) to reduce the resources required to run the experiment. Taking these steps cuts the total number of experiments required by at least 50% (i.e., 16 experiments; 8 for the instrument factors study and 8 for a further sample preparation factors study) instead of 32 (19 parameter resolution III design) or typically 40 (as sample preparation is usually evaluated separately, ignoring centre points). See Figure 5 for a visual representation of how this resource was reduced.


Figure 6: Alias list for 7 factors resolution III design.
In a resolution III study, the two factor interactions are aliased with single factors. Therefore, it is important to allocate the factors carefully to minimise the confusion this can cause during the analysis of the study if the factor is seen to have an effect. It is advisable to review the alias list prior to the finalisation of the design and assess whether the two‑factor interactions aliased with each single factor could have the same effect on any of the responses that are assessed in the study. If the same effect is likely, then factors should be re-allocated to avoid these situations as far as possible, which will make the analysis of the study easier and lower the likelihood of having to perform further experimentation to de-alias factors. The alias list for this study is shown in Figure 6.


Table 4: Allocation of factors.
Given the symmetry of the aliasing pattern, there is little opportunity for smart allocation of factors. However, from the risk assessment, it is known that some parameters have a higher risk than others; also, as a rule, three-factor interactions are less likely than two-factor interactions (which are less likely than single factors). The factors were allocated as in Table 4 to reduce the complexity of the analysis of the study.

A, B and D are low risk groups, making it easy to discard any two‑factor interaction containing any of these factors.

C, F and G are high risk and all the two‑factor interactions they are aliased with contain either A, B or D; therefore, there should not be any ambiguity in determining the cause of an effect.

Had A, B and C been allocated to the low risk parameters, on the other hand, then D, E and F would have been aliased with one two-factor interaction that did not contain any of these low risk parameters, and is therefore more likely (Figure 6). In this later example, the complexity of the analysis of the study would not have been reduced.

Study results

The statistical design used in the case study had additional complications to that outlined because of the need to block runs (i.e., to reduce the number of column and liner changes) and missing results in the data. For these reasons, modelling of the data was complicated and has therefore not been included in this article because the main focus is the design setup. However, a brief summary of the conclusions from the study is given.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
32%
Breakthrough designations
11%
Protecting the supply chain
37%
Expedited reviews of drug submissions
11%
More stakeholder involvement
11%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here